Ethical issues in oncology biostatistics

A medical statistician’s routine professional activitiesare likely to have important ethical consequences. This is due in part to the fact that good medical practice and scientifically valid medical research both require as precursors high quality statistical design and data analysis. In this paper I discuss various ethical issues that I have encountered while working as a biostatistician at M.D. Anderson Cancer Center. I describe particular experiences and the ethical issues involved. Topics include medical decision making, benefit-harm tradeoffs, safety monitoring, adaptive randomization, informed consent, and publication bias.

[1]  W. R. Thompson.  ON THE LIKELIHOOD THAT ONE UNKNOWN PROBABILITY EXCEEDS ANOTHER IN VIEW OF THE EVIDENCE OF TWO SAMPLES , 1933 .

[2]  J. Ware.  Investigating Therapies of Potentially Great Benefit: ECMO , 1989 .

[3]  L. Roth,et al.  Toward an informed discussion of informed consent: a review and critique of the empirical studies. , 1983, Arizona law review.

[4]  J M Lachin,et al.  The use of response-adaptive designs in clinical trials. , 1993, Controlled clinical trials.

[5]  J B Kadane,et al.  Progress toward a more ethical method for clinical trials. , 1986, The Journal of medicine and philosophy.

[6]  M R Conaway,et al.  Designs for phase II trials allowing for a trade-off between response and toxicity. , 1996, Biometrics.

[7]  P F Thall,et al.  Optimal two-stage designs for clinical trials based on safety and efficacy. , 2001, Statistics in medicine.

[8]  T. Beauchamp,et al.  Principles of biomedical ethics , 1991 .

[9]  P F Thall,et al.  New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. Sung,et al.  Selecting Therapeutic Strategies Based on Efficacy and Death in Multicourse Clinical Trials , 2002 .

[11]  B W Turnbull,et al.  Group sequential tests for bivariate response: interim analyses of clinical trials with both efficacy and safety endpoints. , 1993, Biometrics.

[12]  R J Cook,et al.  Coupled error spending functions for parallel bivariate sequential tests. , 1996, Biometrics.

[13]  Approximate Bayesian Evaluation of Multiple Treatment Effects , 2000, Biometrics.

[14]  G W Torrance,et al.  Incorporating Utility-Based Quality-of-Life Assessment Measures in Clinical Trials: Two Examples , 1989, Medical care.

[15]  P F Thall,et al.  Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. , 1998, Statistics in medicine.

[16]  J. Bryant,et al.  Incorporating toxicity considerations into the design of two-stage phase II clinical trials. , 1995, Biometrics.

[17]  A. Willan,et al.  Hypothesis testing and sample size for bivariate binomial response in the comparison of two groups. , 1985, Journal of chronic diseases.

[18]  P Glasziou,et al.  Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P F Thall,et al.  Treatment Comparisons Based on Two‐Dimensional Safety and Efficacy Alternatives in Oncology Trials , 1999, Biometrics.

[20]  P. Thall,et al.  Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. , 1995, Statistics in medicine.

[21]  Anastasios A. Tsiatis,et al.  A consistent estimator for the distribution of quality adjusted survival time , 1997 .

[22]  Stephen G. Eick,et al.  The two-armed bandit with delayed responses , 1988 .

[23]  D. Berry,et al.  Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. , 1995, Statistics in medicine.

[24]  R. Gelber,et al.  Quality adjusted survival analysis. , 1990, Statistics in medicine.

[25]  P F Thall,et al.  Accrual strategies for phase I trials with delayed patient outcome. , 1999, Statistics in medicine.

[26]  William F. Rosenberger,et al.  New directions in adaptive designs , 1996 .

[27]  Joseph B. Kadane,et al.  Bayesian methods and ethics in a clinical trial design , 1996 .

[28]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[29]  Y K Cheung,et al.  Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities , 2000, Biometrics.

[30]  J Whitehead,et al.  Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes , 1999, Biometrics.

[31]  Peter F Thall,et al.  Monitoring the Rates of Composite Events with Censored Data in Phase II Clinical Trials , 2002, Biometrics.

[32]  R. G. Cornell,et al.  Ethics and statistics in randomized clinical trials. , 1991, Statistical science : a review journal of the Institute of Mathematical Statistics.